Shares of Australian cannabis company Melodiol Global Health (ASX:ME1) surged as much as 20% to A$0.0060.

The company reports that its Canadian wing received three new purchase orders worth A$740,022.

There was further good news, as the unit had its highest sales week in Nova Scotia, Canada, taking place between September 11 and September 17.

These results come in contrast to the declining performance of the stock which noted a 75% drop Year-to-Date (YTD) at the last close, despite a 0.43% increase in the benchmark S&P/ASX 200 index.

Melodiol Global Health is a firm specializing in the cultivation and sale of medical cannabis.